Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study

Annalisa Trama1, Claudia Proto2, Diego Signorelli2, Marina C. Garassino2, Giuseppe Lo Russo2, Monica Ganzinelli2, Arsela Prelaj2, Carolina Mensi3, Manuela Gangemi4, Valerio Gennaro5, Elisabetta Chellini6, Adele Caldarella6, Italo F. Angelillo6, Valeria Ascoli6, Cristiana Pascucci7, Giovanna Tagliabue1, Rosanna Cusimano1 & the LUME study WG

1 Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
2 Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
3 COR Lombardy, Epidemiology Unit, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
4 Unit of Cancer Epidemiology, University of Turin and CPO-Piemonte, Turin, Italy
5 COR Liguria, UO Epidemiology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
6 Unit of Occupational & Environmental Epidemiology, Tuscan Occupational Cancer Registry, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
7 Tuscan Cancer Registry, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
8 Department of Experimental Medicine, COR Campania, University of Campania “Luigi Vanvitelli”, Naples, Italy
9 Department of Radiological Sciences, Oncology and Anatomical Pathology, COR Lazio, University La Sapienza, Rome, Italy
10 Mesothelioma Marche Registry - COR Marche, School of Medicinal and Health Products Sciences, University of Camerino, Camerino, Italy
11 Varese Cancer Registry, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
12 Palermo Cancer Registry, Palermo, Italy
13 Integrated Cancer Registry of Catania-Messina-Siracusa-Enna, Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele, Catania, Italy
14 Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Forlì, Italy
15 COR Veneto, Occupational Health Unit, Department of Prevention, Padua, Italy
16 Sec. Public Health, Department of Experimental Medicine, COR Umbria, University of Perugia, Perugia, Italy
17 Siracusa Cancer Registry, Siracusa, Italy
18 Parma Cancer Registry, Parma, Italy
19 Como Cancer Registry, Como, Italy
20 Servizio di Epidemiologia, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy
21 U.O.S.D. Napoli 3 South Cancer Registry, Piazza San Giovanni, Naples, Italy
22 Modena Cancer Registry, Modena, Italy
23 Cancer Registry and Histopathology Department, COR Sicily, ‘Civic -M.P. Arezzo’ Hospital, Ragusa, Italy
24 Trapani Cancer Registry, Trapani, Italy
25 Sondrio Cancer Registry, Sondrio, Italy
26 Trento Cancer Registry, Servizio Epidemiologia Clinica e Valutativa, Azienda Provinciale per i Servizi Sanitari, Trento, Italy
27 Department of Medicine and Surgery, University of Parma, Parma, Italy

Keywords
Logistic models; mesothelioma malignant; registries; therapeutics.

Abstract
Background: Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. Centralization of rare cancer in dedicated centers is recommended to ensure expertise, multidisciplinarity and access to innovation. In Italy, expert centers for MPM have not been identified in all regions. We aimed to describe the treatment patterns among MPM patients across different Italian regions and to identify factors associated with the treatment patterns across the regions.

Methods: We performed an observational study on a random sample of 2026 MPM patients diagnosed in 2003–2008. We included 26 population-based...
registries covering 70% of the Italian population. To identify factors associated with treatment patterns, across the different regions, we fitted a multinomial logistic regression model adjusted by age, sex, stage, histology and hospital with thoracic surgical department.

**Results:** MPM patients mostly received chemotherapy alone (41%) or no cancer-directed therapy (36%) especially the older patients. The first course of treatment for MPM patients differed across regions. Patients from Piedmont, Liguria and Campania were more likely to receive no cancer-directed therapy; those living in Tuscany and Sicily were more likely to get surgery; patients from Marche and Lazio were more likely to receive chemotherapy. These differences were not explained by age, sex, stage, histology and availability of a thoracic surgery department.

**Conclusions:** There is limited expertise available and lack of a network able to maximize the expertise available may contribute to explaining the results of our study. Our findings support the need to ensure the appropriate care of all MPM patients in reorganizing the health care services.

**Key points**

**Significant findings of the study:**
MPM patients mostly received chemotherapy alone or no cancer-directed therapy especially the older patients. The first course of treatment for MPM patients differed across Italian regions.

**What this study adds:**
Differences in MPM clinical management are not explained by the age, stage, histology nor by the availability of a thoracic surgery department. Limited expertise for MPM contribute to explaining the unequal access to appropriate care for MPM patients in Italy.

**Introduction**

Malignant pleural mesothelioma (MPM) is a rare tumour strongly associated with asbestos exposure. In Europe, the MPM incidence rates (IR) are expected to peak around 2020 in some countries, but a decrease may have already begun in others as a consequence of legislative restrictions implemented in the 1980s. In Italy, a downturn in the occurrence of MPM is expected to occur after 2019. However, 1450 new MPM (IR 3.3 and 0.9 in males and females, respectively) patients were diagnosed in 2014 and the IR across Italian geographical areas ranged from <4/100 000 to >100/100 000.

MPM has a poor prognosis (five-year survival 9%) and no survival progresses have been observed at population level during the last decades. Traditionally, the centralization of rare cancer in dedicated centers has been recommended to ensure expertise, multidisciplinarity and access to innovation. Nevertheless, this process requires health migration, rationing of resources and a potential failure in routine care since the limited expert resources may be overwhelmed, determining waiting lists. By ensuring appropriate care of all patients regardless of the point of access, networking seems to be the most appropriate answer to rare cancers such as MPM. In Italy, specialized centers for MPM patients have not been identified in all regions and, up to 2017, only an informal professional network on rare cancers, focused mainly on sarcoma tumors, was created to provide second opinion and clinical advice on rare cancers.

Against this background, we aimed to: (i) Describe the treatment patterns among MPM patients in Italy and across Italian regions; and (ii) identify patients and health care system factors associated with treatment patterns across Italian regions.

**Methods**

This population-based study is part of the wider “MPM survivors in Italy: what is contributing to long term survival?” (LUME) project. The LUME project collaborated with 26 population-based registries to develop a national, population-based database of MPM patients with demographic and
clinical information. Regional registries (centri operativi regionali-COR) from the National mesothelioma-dedicated surveillance system and general cancer registries (CRs) contributed to the LUME database. General CRs were used when a COR either was not available in a region, or did not accept a request to join the study. The 26 registries involved covered 70% of the Italian population (Fig 1) and registered 80% of all MPM cases in Italy. Veneto COR contributed with the Padua province data only; however, we will refer to it as Veneto region; Trento CR will be referred to as Trentino Alto Adige region; Siracusa, Trapani, Palermo, Catania-Messina and Ragusa CRs will be referred to as Sicily region and Parma, Reggio Emilia, Modena and Romagna CRs as Emilia-Romagna region (Fig 1).

About 5600 MPM, histologically or cytologically confirmed, were identified from 2003 to 2008 by the registries involved in the LUME project. Patients diagnosed from death certificate or autopsy were excluded. Clinical information are not routinely collected by these registries thus an ad hoc data collection was organized to retrieve them including diagnostic procedures, histology, clinical and pathological stage, treatment information (surgery [SRG], radiotherapy [RT], chemotherapy [CHT] and best supportive care [BSC]), hospital of origin (including information on the availability of an onsite thoracic surgical department), and follow-up. Data collection was based on a common protocol, agreed by a multidisciplinary group including registrars, epidemiologist and MPM clinical experts (pathologists, surgeons and oncologists).

Due to restricted financial resources the LUME project could not collect data for all the 5600 cases but for a representative random sample of 2026 MPM patients, taking into consideration the relative numerical contribution of each registry.

Clinical and pathological T, N and M were those defined by the clinicians. The TNM Staging System proposed from the International Mesothelioma Interest Group was used for the analyses.9

We defined the first course of treatment as the one started within five months from the diagnosis:

- Surgery alone (including extra pleural pneumonectomy [EPP], pleurectomy with decortications [P/D] and pleurectomy);
- Chemotherapy alone;
- Chemotherapy and surgery (SRG + CHT);
- Multimodal approach consisting of EPP + radical RT + CHT;
- Other treatment combinations (including SRG + radical RT; CHT + radical RT; surgery≠EPP + radical RT + CHT);
- No treatment (including also BSC);
- Missing information.

For the treatment time frame please refer to Supplementary material B, Table S1.

We used standard age groups: 15–54; 55–64; 65–74 and 75+.10

To identify factors associated with patterns of treatment across the different Italian geographical areas, we fitted a multinomial logistic regression model, considering as the dependent variable the most common treatment options (CHT or SRG alone, SRG + CHT, no active treatment) with “CHT alone” acting as reference. We included as the independent variables patients/tumors characteristics available in the LUME database (age, sex, stage and histology), Italian regions and health care system factors possibly associated with receipt of MPM treatment (ie, availability of a thoracic surgery department in the hospitals). For the independent variables, the category with highest frequency was the reference (ref). The output of this model is the relative risk ratio (RRR) of those who received a specific treatment versus “CHT alone”. Two-sided P-values<0.05 were considered significant.

All statistical analyses were performed using Stata, release 13.0 (Stata Corporation, College Station, TX, USA).
Results

Clinical and demographic patient’s characteristics are summarized in Table 1. Of 2026 MPM patients, 67% were diagnosed with cancer at 65 years or more (average age: 69 years), 71% were males and 68% with epitheliod histotype. Around half of patients (46%) were diagnosed with stage I–II of disease and 41% were treated with CHT alone. EPP, P/D and pleurectomy were used in 40%, 30% and 24% of the MPM surgically treated, respectively.

A description of the first course of treatment by stage and age groups is reported in Table 2. Regardless stage, CHT was the most common treatment option at all ages, apart from elderly patients (75+ years) who received less active treatments and more BSC compare to younger patients. MPM patients with stage I–II and III were more likely to be treated with SRG as compared to those diagnosed with stage IV. The type of SRG (EPP, P/D or pleurectomy) did not differ much across the stages. Younger patients (<65 years) were most likely to receive the EPP, SRG+/-CHT use decreased with increasing age. Combined and multimodal approaches were used more for younger patients (<65 years).

In all regions most of MPM patients were males and with epitheliod histotype (Supplementary material B, Table S2). MPM patients’ age distribution by geographical areas in our sample corresponded to the age distribution in the general population,11 older patients were diagnosed in the center and north west of Italy (eg, Tuscany, Liguria, Marche, Umbria) whereas in southern Italy (eg, Campania, Sicily) the patients were younger (Supplementary material B, Table S2). Patients were mainly diagnosed with stage I–II across regions with differences ranging from about 30% in Sicily and Trentino Alto Adige to 57% in Lombardy (Table 3a). Whereas patients with stage III and IV were diagnosed mostly in Trentino Alto Adige, Veneto, Umbria and Emilia-Romagna (Table 3a). Compared to the other regions, in Tuscany and Sicily patients were more likely to be treated with SRG+/-CHT (34% and 27%, respectively) whereas in Liguria and Piedmont patients

### Table 1 Demographic and clinical characteristics of malignant pleural mesothelioma patients diagnosed 2003–2008 in the LUME study

| Variable | Category | No. of cases | % |
|----------|----------|--------------|---|
| Total | 2026 | 100 |
| Age class | 15–54 | 188 | 9.3 |
| | 55–64 | 475 | 23.4 |
| | 65–74 | 733 | 36.2 |
| | 75+ | 630 | 31.1 |
| Sex | Male | 1438 | 71 |
| | Female | 588 | 29 |
| Histotype | Epitheliod | 1384 | 68.3 |
| | Not otherwise specified | 236 | 11.7 |
| | Biphasic | 229 | 11.3 |
| | Sarcomatoid | 177 | 8.7 |
| Diagnostic confirmation | Histological | 1917 | 94.6 |
| | Cytological | 109 | 5.4 |
| Imaging | CT scan or/and PET or/and MRI | 1818 | 89.7 |
| | X-ray alone | 164 | 8.1 |
| | None | 44 | 2.2 |
| Clinical stage† | Stage I–II | 928 | 45.8 |
| | Stage III | 375 | 18.5 |
| | Stage IV | 426 | 21.0 |
| | Missing information | 297 | 14.7 |
| First course of treatment | Surgery alone | 135 | 6.7 |
| | Surgery and chemotherapy | 206 | 10.2 |
| | Chemotherapy alone | 833 | 41.1 |
| | Multimodal treatment | 17 | 0.8 |
| | Other combination of treatments | 21 | 1 |
| | No treatment or best supportive care | 739 | 36.5 |
| | Missing information | 75 | 3.7 |
| Information on the type of surgery (over 341 surgery ± chemotherapy treated patients) | Extra pleural pneumonectomy | 134 | 39.3 |
| | Pleurectomy with decortication (P/D) | 101 | 29.6 |
| | Pleurectomy | 82 | 24.1 |
| | Information on type of surgery missing | 24 | 7 |

†AJCC.9
were less likely to be treated (no treatment in 50% and 46%, respectively) (Table 3b). CHT use varied across geographical areas ranging from about 71% in Trentino Alto Adige to 28% in Campania (Table 3b). EPP was the most used type of surgery in all regions except for Campania, Tuscany, Umbria and Piedmont (data available from the corresponding author).

The model results (Table 4) confirmed that SRG (RRR = 2.35) use was more common than CHT in young MPM patients (15–54 years) compared to 65–74 years old. In addition, old MPM patients (RRR = 5.32), those with missing information on stage (RRR = 2.33), females (RRR = 1.47) and those with not specified and sarcomatoid histotype (RRR = 1.7 and RRR = 1.8) were more likely to get BSC than CHT (Table 4). Use of SRG+/-CHT was more common than CHT alone in MPM patients with stage I–II compared to all other stages. Finally, the availability of a thoracic surgery onsite increased the likelihood to receive SRG + CHT (RRR = 2.23).

The model results showed that considering system level characteristics (ie, availability of a thoracic surgical department) did not fully explain the differences in first course of treatment observed across the Italian regions. Thus, compared to MPM patients living in Lombardy and getting CHT alone, after adjusting for age, sex, histology, stage and thoracic surgery onsite MPM patients living in:

- Piedmont, Liguria and Campania had a higher RRR to be untreated,
- Tuscany and Sicily had a higher RRR to get treatment including SRG,
- Marche and Sicily had a lower RRR to be untreated and,
- Lazio had a lower RRR to get SRG + CHT (than so more likely to receive CHT alone).

Table 2  First course of treatment for malignant pleural mesothelioma patients included in the study by stage and by age and stage

| Overall stage | No. of cases | Surgery alone | Chemotherapy alone | Surgery and chemotherapy | Multimodal treatment | Other combination of treatments | No treatment or BSC† | Missing information |
|---------------|--------------|---------------|--------------------|--------------------------|----------------------|-------------------------------|---------------------|---------------------|
| Stage I–II    | 928          | 8.8           | 39                 | 13.3                     | 1.3                  | 0.7                           | 33.6                | 3.3                 |
| Stage III     | 375          | 6.8           | 50.1               | 7.2                      | 0.5                  | 0.5                           | 31.7                | 3.2                 |
| Stage IV      | 426          | 3.8           | 47.2               | 8.5                      | 0.2                  | 2.8                           | 35.5                | 2                   |
| Missing       | 297          | 3.7           | 29                 | 6.4                      | 0.7                  | 0.7                           | 52.2                | 7.3                 |
| Overall       | 2026         | 6.6           | 41.3               | 10.1                     | 0.8                  | 1.1                           | 36.4                | 3.7                 |
| 15–54 years old |             |               |                    |                          |                      |                               |                     |                     |
| Stage I–II    | 79           | 13.9          | 38.0               | 30.4                     | 2.5                  | 0.0                           | 10.1                | 5.1                 |
| Stage III     | 47           | 6.4           | 51.1               | 6.4                      | 2.1                  | 2.1                           | 27.7                | 4.2                 |
| Stage IV      | 42           | 11.9          | 52.4               | 14.3                     | 0.0                  | 2.4                           | 14.3                | 4.7                 |
| Missing       | 20           | 15.0          | 40.0               | 15.0                     | 0.0                  | 0.0                           | 20.0                | 10.0                |
| Overall       | 188          | 11.7          | 44.7               | 19.1                     | 1.6                  | 1.1                           | 16.5                | 5.3                 |
| 55–64 years old |             |               |                    |                          |                      |                               |                     |                     |
| Stage I–II    | 215          | 10.7          | 44.7               | 21.9                     | 2.3                  | 1.4                           | 17.7                | 1.3                 |
| Stage III     | 88           | 9.1           | 48.9               | 18.2                     | 1.1                  | 0.0                           | 17.1                | 5.6                 |
| Stage IV      | 109          | 3.7           | 51.4               | 16.5                     | 0.0                  | 4.6                           | 22.0                | 1.8                 |
| Missing       | 63           | 4.8           | 42.9               | 11.1                     | 0.0                  | 0.0                           | 31.8                | 9.4                 |
| Overall       | 475          | 8.0           | 46.7               | 18.5                     | 1.3                  | 1.7                           | 20.4                | 3.4                 |
| 65–74 years old |             |               |                    |                          |                      |                               |                     |                     |
| Stage I–II    | 337          | 8.9           | 47.8               | 12.5                     | 1.5                  | 0.6                           | 24.9                | 3.8                 |
| Stage III     | 141          | 5.7           | 63.1               | 5.7                      | 0.0                  | 0.0                           | 24.1                | 1.4                 |
| Stage IV      | 161          | 3.1           | 59.6               | 6.2                      | 0.6                  | 2.5                           | 26.1                | 1.9                 |
| Missing       | 94           | 2.2           | 37.2               | 9.6                      | 2.1                  | 2.1                           | 40.4                | 6.4                 |
| Overall       | 733          | 6.1           | 52.0               | 9.4                      | 1.1                  | 1.1                           | 27.0                | 3.3                 |
| 75+ years old |             |               |                    |                          |                      |                               |                     |                     |
| Stage I–II    | 297          | 6.1           | 25.3               | 3.4                      | 0.0                  | 0.3                           | 61.3                | 3.6                 |
| Stage III     | 99           | 6.1           | 32.3               | 0.0                      | 0.0                  | 0.0                           | 57.6                | 3.0                 |
| Stage IV      | 114          | 1.8           | 23.7               | 1.8                      | 0.0                  | 1.7                           | 69.3                | 1.7                 |
| Missing       | 120          | 2.5           | 13.3               | 0.0                      | 0.0                  | 0.0                           | 77.5                | 6.7                 |
| Overall       | 630          | 4.6           | 23.8               | 1.9                      | 0.0                  | 0.6                           | 65.3                | 3.8                 |

†Best supportive care.
No major differences were confirmed across the other geographical areas.

**Discussion**

This is the first population-based study to provide a description of the treatment patterns up to 2008 for MPM patients in Italy and across different Italian geographical areas. It is the results of a unique collaborative effort including 26 registries from 12 of 21 Italian regions corresponding to 70% of the Italian population. Previous Italian studies analyzed survival of MPM patients with limited information on treatment and generally were focused on one region. In our study, 36% MPM patients did not receive active cancer treatment, especially elderly patients (65%) independently of disease stage. However, in our database we had not got the information to distinguish MPM patients unsuitable for systemic therapy from those untreated because they were most likely under observation. Our results are similar to those reported in 2011 in the USA, and 29% of MPM who did not receive active cancer treatment were principally older patients. Therapeutic decisions in the elderly with cancer should not be based just on chronological age but should also take into account the patient preferences, functional age, presence of comorbidities and estimated benefits and risks.

In our study, 41% received chemotherapy alone. MPM patients were also reported to be mainly treated with CHT in Belgium (60%), Netherlands (41%) and England (37%). In Slovenia, the number of patients treated with CHT increased from 32% in 1999–2003 to 80% in 2004–2008 due to the systematic introduction of CHT. Also, in the USA in 2011, MPM patients receiving systemic therapy were 60%.

---

**Table 3** Distribution of clinical stage (a) and the first course of treatment (b) of malignant pleural mesothelioma patients included in the study, by Italian geographical areas

(a) Italian geographical areas† | No. of cases | Clinical stage (%) |  |
--- | --- | --- | --- | --- | --- |
| | | Stage I–II | Stage III–IV | Missing |
| Lombardy | 455 | 57 | 41 | 2 |
| Piedmont | 371 | 50 | 32 | 18 |
| Tuscany | 192 | 48 | 26 | 26 |
| Umbria | 39 | 46 | 51 | 3 |
| Liguria | 200 | 44 | 34 | 22 |
| Marche | 75 | 44 | 47 | 9 |
| Emilia-Romagna | 118 | 42 | 50 | 9 |
| Veneto | 37 | 41 | 51 | 8 |
| Lazio | 156 | 39 | 49 | 12 |
| Campania | 207 | 39 | 44 | 17 |
| Trentino-Alto Adige | 7 | 29 | 71 | 0 |
| Sicily | 169 | 27 | 43 | 30 |

(b) Italian geographical areas† | No. of cases | First course of treatment (%)‡ |  |
--- | --- | --- | --- | --- | --- |
| | | Chemotherapy alone | Surgery ± chemotherapy | No treatment or best supportive care | Missing |
| Trentino-Alto Adige | 7 | 71 | 14 | 14 | 0 |
| Marche | 75 | 59 | 17 | 20 | 0 |
| Lazio | 156 | 51 | 10 | 40 | 0 |
| Veneto | 37 | 49 | 16 | 22 | 11 |
| Sicily | 169 | 47 | 27 | 21 | 4 |
| Lombardy | 455 | 45 | 17 | 34 | 0 |
| Umbria | 39 | 44 | 10 | 41 | 0 |
| Emilia-Romagna | 118 | 43 | 16 | 36 | 2 |
| Piedmont | 371 | 40 | 12 | 46 | 0 |
| Liguria | 200 | 36 | 13 | 50 | 1 |
| Tuscany | 192 | 32 | 34 | 30 | 4 |
| Campania | 207 | 28 | 11 | 35 | 25 |

†The ranking of the Italian geographical areas is the % of stage I–II in Table 3a and the % of chemotherapy alone in Table 3b. §The sum of each row, Italian geographical areas, does not add up at 100% due to the lack of inclusion of multimodal and other combination of treatments that occurred in few cases across the regions.
In our study, 19% received a treatment including SRG. In Europe, surgery was used in 27%, 10% and 5% MPM patients in Belgium, England and Netherlands, respectively (years of diagnosis 2006–2011). In Slovenia, the number of patients treated by surgery decreased from 21% in 1990–2004 to 9% in 2005–2009. In the USA, cancer-directed surgery was reported in 22%, 23% and 27% in MPM patients in the years 1990–2004, 1973–2009 and 2011, respectively. The available data showed a heterogeneity of treatment across geographical areas and time periods. However, CHT was confirmed as the main treatment option for MPM patients in most EU countries and USA while the multimodal approach had a limited use worldwide. These reports pre-date the results of the MARS study and enhance the support that patients who are candidates for a multimodal approach should be included in clinical trials at highly specialized centers. In the last decade, no developments have been observed regarding systemic treatment. Cisplatin and pemetrexed have remained the standard of care in MPM patients for around 20 years. Recently, various studies have explored the role of immunotherapy and its combination with standard CHT in advanced MPM patients and preliminary results seems to predict a better survival rate compared to CHT alone. Nevertheless, it appears that CHT is the best treatment option.

Our results showed that the majority of patients are diagnosed with stage I–II and 21% with stage IV. In the USA, two studies reported that only 11% MPM patients are diagnosed with early disease and patients diagnosed with distant disease range from 16% to 59%. Stage definition and study period could explain the differences in stage distribution across these studies. Another study in the USA reported 28% were stage I and II; 14% stage III, 29% stage IV with 29% of stage information missing from 2005 to 2009. In our study, missing information was around 15%; 90% of cases were staged based on CT scan/RMI/PET. In any case, we cannot rule out a possible stage misclassification also in our data considering the interpersonal variability of the radiologists.

In our study, 19% received a treatment including SRG. In Europe, surgery was used in 27%, 10% and 5% MPM patients in Belgium, England and Netherlands, respectively (years of diagnosis 2006–2011). In Slovenia, the number of patients treated by surgery decreased from 21% in 1990–2004 to 9% in 2005–2009. In the USA, cancer-directed surgery was reported in 22%, 23% and 27% in MPM patients in the years 1990–2004, 1973–2009 and 2011, respectively. The available data showed a heterogeneity of treatment across geographical areas and time periods. However, CHT was confirmed as the main treatment option for MPM patients in most EU countries and USA while the multimodal approach had a limited use worldwide. These reports pre-date the results of the MARS study and enhance the support that patients who are candidates for a multimodal approach should be included in clinical trials at highly specialized centers. In the last decade, no developments have been observed regarding systemic treatment. Cisplatin and pemetrexed have remained the standard of care in MPM patients for around 20 years. Recently, various studies have explored the role of immunotherapy and its combination with standard CHT in advanced MPM patients and preliminary results seems to predict a better survival rate compared to CHT alone. Nevertheless, it appears that CHT is the best treatment option.

Our results showed that the majority of patients are diagnosed with stage I–II and 21% with stage IV. In the USA, two studies reported that only 11% MPM patients are diagnosed with early disease and patients diagnosed with distant disease range from 16% to 59%. Stage definition and study period could explain the differences in stage distribution across these studies. Another study in the USA reported 28% were stage I and II; 14% stage III, 29% stage IV with 29% of stage information missing from 2005 to 2009. In our study, missing information was around 15%; 90% of cases were staged based on CT scan/RMI/PET. In any case, we cannot rule out a possible stage misclassification also in our data considering the interpersonal variability of the radiologists.
In our study, we found that the first course of treatment for MPM patients differed across geographical areas. The observed differences could be due to the different availability of a thoracic surgery department but, as showed by the proposed model, these factors did not fully explain the observed differences on treatment approach across regions. We believe that these differences may be due to the limited expertise available for a rare cancer such as MPM and also to the lack of a network able to maximize the available expertise.

In Italy, three consensus conferences on the management of MPM took place in 2011, 2013 and 2015 to develop recommendations on MPM management for public health institutions, clinicians and patients. From the health care organization, some regions (eg, Emilia-Romagna) have identified a clinical network for the management of MPM patients. More importantly, the Italian rare cancers network was established by a formal agreement between the Ministry of Health and the different Italian Regions (“Intesa Stato-Regioni”) in September 2017. The time of our analyses (patients diagnosed in 2003–2008) pre-dates implementation of regional and national initiatives to ameliorate the quality of care for MPM patients and thus provides important baseline data to evaluate such initiatives. Limitations of our study include the lack of information on comorbidity and performance status, which is relevant for interpreting the treatment choice. Strengths are the centralization of data quality checks and analyses along with the population-based nature of this effort.

In the future, population-based data will be crucial to assess whether changes in management policies have the desired effect to ensure the best care for all MPM patients.

Acknowledgments

This work was supported by Associazione Italiana per la Ricerca sul Cancro (Italian Association for cancer research-AIRC) (Investigator Grant - IG 2012 number 13534, year 2012), the Italian Ministry of Health (RF-INT-201241451, year 2008) and the Associazione Italiana Esposti Amianto (Italian Association of Asbestos Exposures AIEA).

Disclosure

All authors declare no competing interests.

References

1 Gatta G, Capocaccia R, Bottà L et al. Burden and centralised treatment in Europe of rare tumours: Results of RARECAREnet – A population-based study. Lancet Oncol 2017; 18: 1022–39.
2 Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E. The mesothelioma epidemic in Western Europe: An update. Br J Cancer 2004; 90: 1022–4.
3 Montanaro F, Bray F, Gennaro V et al. Pleural mesothelioma incidence in Europe: Evidence of some deceleration in the increasing. (Published erratum appears in Cancer Causes Control 2004; 15: 103.). Cancer Causes Control 2003; 8: 791–803.
4 Mensi C, De Matteis S, Dallari B, Riboldi L, Bertazzi PA, Consonni D. Incidence of mesothelioma in Lombardy, Italy: Exposure to asbestos, time patterns and future projections. Occup Environ Med 2016; 73 (9): 607–13.
5 VI Rapporto ReNaM. [Cited 16 Feb 2020] Available from URL: https://www.inail.it/cs/internet/comunicazione/pubblicazioni/catalogo-generale/pubbl-registro-nazionale-mesoteliomi-6-rapporto.html.
6 I numeri del cancro 2018. [Cited 16 Feb 2020] Available from URL: http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?menu=notizie&id=3494.
7 Frezza AM, Trama A, Blay JY, Casali PG. Networking in rare cancers: What was done, what’s next. Eur J Surg Oncol 2019; 45 (1): 16–8.
8 Sanfilippo R, Tricomi M, Grosso F et al. The Italian rare cancer network. JCO 2012; 30 (15): 10053–3.
9 Rush VW. A proposed new international TNM staging system for malignant pleural mesothelioma’ from the international mesothelioma interest group. Lung Cancer 1996; 14 (1): 1–12.
10 Montanaro F, Rosato R, Gangemi M et al. Survival of pleural malignant mesothelioma in Italy: A population-based study. Int J Cancer 2009; 124: 201–7.
11 Italian National Institute of Statistics (ISTAT). Italian population by region and age. [Cited 15 Jul 2019.] Available from URL: http://www.demo.istat.it/pop2012/index3.html.
12 Marinaccio A, Nesti M, Regional Operational Centers. Analysis of survival of mesothelioma cases in the Italian register (ReNaM). Eur J Cancer 2003; 39 (9): 1290–5.
13 Barbieri PG, Marinaccio A, Ferrante P, Scarselli A, Pinelli V, Tassi G. Effects of combined therapies on the survival of pleural mesothelioma patients treated in Brescia, 1982-2006. Tumori 2012; 98 (2): 215–9.
14 Carioli G, Bonifazi M, Rossi M et al. Management and survival of pleural mesothelioma: A record linkage study. Respiration 2018; 95 (6): 405–13.
15 Ennewold L, Sharon E, Thomas A. Patterns of care and survival among patients with malignant mesothelioma in the United States. Lung Cancer 2017; 112: 102–8.
16 Pallis AG, Fortpied C, Wedding U et al. EORTC elderly task force position paper: Approach to the older cancer patient. Eur J Cancer 2010; 46 (9): 1502–13.
17 Ceresoli GL, Grosso F, Zucali PA et al. Prognostic factors in elderly patients with malignant pleural mesothelioma: Results of a multicenter survey. Br J Cancer 2014; 111 (2): 220–6.
18 Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and
survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, The Netherlands and England. *Lung Cancer* 2015; 89 (2): 212–7.

19 Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. *Radiol Oncol* 2012; 46 (2): 136–44.

20 Flores RM, Riedel E, Donington JS et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (surveillance, epidemiology, and end results [SEER]) population. *J Thorac Oncol* 2010; 5 (10): 1649–54.

21 Taioli E, Wolf AS, Camacho-Rivera M et al. Determinants of survival in malignant pleural mesothelioma: A surveillance, epidemiology, and end results (SEER) study of 14,228 patients. *PLOS One* 2015; 10 (12): e0145039.

22 Treasure T, Lang-Lazdunski L, Waller D et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. *Lancet Oncol* 2011; 12 (8): 763–72.

23 Baas P, Fennell D, Kerr KM et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines. *Ann Oncol* 2015; 26 (5): v31–9.

24 AIOM 2018 Clinical Practice Guidelines. [Cited 16 Feb 2020.] Available from URL: https://www.aiom.it/linee-guida/linee-guida-aiom-2018-mesotelioma-pleurico/.

25 Novello S, Pinto C, Torri V et al. The third Italian consensus conference for malignant pleural mesothelioma: State of the art and recommendations. *Crit Rev Oncol Hematol* 2016; 104: 9–20.

26 Beebe-Dimmer JL, Fryzek JP, Yee CL et al. Mesothelioma in the United States: A surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival. *Clin Epidemiol* 2016; 8: 743–50.

27 Rusch VW, Gill R, Mitchell A et al. A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma. *Ann Thorac Surg* 2016; 102 (4): 1059–66.

28 Pinto C, Ardizzoni A, Betta PG et al. Expert opinions of the first Italian consensus conference on the management of malignant pleural mesothelioma. *Am J Clin Oncol* 2011; 34 (1): 99–109.

29 Pinto C, Novello S, Torri V et al. Second Italian consensus conference on malignant pleural mesothelioma: State of the art and recommendations. *Cancer Treat Rev* 2013; 39 (4): 328–39.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Appendix S1.** LUME Study Working Group.

**Table S1.** Definition of first course of treatment collected in the LUME study.

**Table S2.** Demographic characteristics and histotype of malignant pleural mesothelioma patients included in the LUME study by Italian geographical areas.